| Literature DB >> 26551751 |
Mainul Husain1, Zdenka O Kyjovska2, Julie Bourdon-Lacombe3, Anne T Saber4, Keld A Jensen5, Nicklas R Jacobsen6, Andrew Williams7, Håkan Wallin8, Sabina Halappanavar9, Ulla Vogel10, Carole L Yauk11.
Abstract
Inhalation of carbon black nanoparticles (CBNPs) causes pulmonary inflammation; however, time course data to evaluate the detailed evolution of lung inflammatory responses are lacking. Here we establish a time-series of lung inflammatory response to CBNPs. Female C57BL/6 mice were intratracheally instilled with 162 μg CBNPs alongside vehicle controls. Lung tissues were examined 3h, and 1, 2, 3, 4, 5, 14, and 42 days (d) post-exposure. Global gene expression and pulmonary inflammation were assessed. DNA damage was evaluated in bronchoalveolar lavage (BAL) cells and lung tissue using the comet assay. Increased neutrophil influx was observed at all time-points. DNA strand breaks were increased in BAL cells 3h post-exposure, and in lung tissues 2-5d post-exposure. Approximately 2600 genes were differentially expressed (± 1.5 fold; p ≤ 0.05) across all time-points in the lungs of exposed mice. Altered transcript levels were associated with immune-inflammatory response and acute phase response pathways, consistent with the BAL profiles and expression changes found in common respiratory infectious diseases. Genes involved in DNA repair, apoptosis, cell cycle regulation, and muscle contraction were also differentially expressed. Gene expression changes associated with inflammatory response followed a biphasic pattern, with initial changes at 3h post-exposure declining to base-levels by 3d, increasing again at 14 d, and then persisting to 42 d post-exposure. Thus, this single CBNP exposure that was equivalent to nine 8-h working days at the current Danish occupational exposure limit induced biphasic inflammatory response in gene expression that lasted until 42 d post-exposure, raising concern over the chronic effects of CBNP exposure. CrownEntities:
Keywords: Biphasic response; Carbon black nanoparticles; Cell cycle regulation; DNA repair; Inflammation; Muscle contraction
Mesh:
Substances:
Year: 2015 PMID: 26551751 PMCID: PMC7103116 DOI: 10.1016/j.taap.2015.11.003
Source DB: PubMed Journal: Toxicol Appl Pharmacol ISSN: 0041-008X Impact factor: 4.219
Inflammatory cell counts in bronchoalveolar lavage (BAL) fluid of C57BL/6 mice exposed to 162 μg of CBNPs at eight different post-exposure time-points. The number of cells is expressed as ± standard error of the mean (SEM) × 103.
| Time-points | Cell types | Number of cells × 103 | |
|---|---|---|---|
| Control | CBNPs | ||
| 3 h | Neutrophils | 3.9± 1.2 | 26.7 ± 5.5 |
| Macrophages | 38.2 ± 8.3 | 46.7 ± 3.1 | |
| Eosinophils | 0.7 ± 0.2 | 0.6 ± 0.2 | |
| Lymphocytes | 0.4 ± 0.2 | 0.1 ± 0.1 | |
| Epithelial | 16.6 ± 2.7 | 42.6 ± 3.6 | |
| Total BAL cells | 59.7 ± 11.4 | 116.8 ± 7.7 | |
| 1 d | Neutrophils | 4.1 ± 1.0 | 123.4 ± 8.4 |
| Macrophages | 39.8 ± 5.4 | 44.2 ± 8.4 | |
| Eosinophils | 1.9 ± 1.2 | 7.1 ± 2.4 | |
| Lymphocytes | 0.6 ± 0.2 | 1.0 ± 0.6 | |
| Epithelial | 11.0 ± 3.1 | 14.2 ± 2.2 | |
| Total BAL cells | 57.3 ± 3.9 | 189.8 ± 12.1 | |
| 2 d | Neutrophils | 4.0 ± 2.3 | 97.4 ± 6.4 |
| Macrophages | 56.8 ± 8.3 | 50.8 ± 5.0 | |
| Eosinophils | 2.3 ± 0.9 | 2.5 ± 1.0 | |
| Lymphocytes | 1.3 ± 0.4 | 1.6 ± 0.4 | |
| Epithelial | 22.4 ± 4.3 | 16.0 ± 1.9 | |
| Total BAL cells | 86.9 ± 11.4 | 168.4 ± 9.8 | |
| 3 d | Neutrophils | 2.0 ± 0.8 | 84.5 ± 6.0 |
| Macrophages | 48.9 ± 13.5 | 65.0 ± 5.3 | |
| Eosinophils | 1.3 ± 0.4 | 3.7 ± 1.9 | |
| Lymphocytes | 0.6 ± 0.2 | 3.3 ± 1.1 | |
| Epithelial | 13.0 ± 3.3 | 14.5 ± 2.7 | |
| Total BAL cells | 65.9 ± 17.5 | 171.1 ± 7.1 | |
| 4 d | Neutrophils | 0.4 ± 0.2 | 80.0 ± 9.0 |
| Macrophages | 38.6 ± 8.2 | 62.5 ± 7.2 | |
| Eosinophils | 0.8 ± 0.7 | 11.0 ± 2.9 | |
| Lymphocytes | 0.2 ± 0.1 | 8.1 ± 1.4 | |
| Epithelial | 9.3 ± 1.0 | 15.1 ± 4.3 | |
| Total BAL cells | 49.2 ± 9.3 | 176.8 ± 13.1 | |
| 5 d | Neutrophils | 0.2 ± 0.1 | 90.6 ± 12.9 |
| Macrophages | 40.0 ± 6.0 | 89.6 ± 6.5 | |
| Eosinophils | 9.1 ± 5.6 | 20.4 ± 9.4 | |
| Lymphocytes | 1.5 ± 0.7 | 16.9 ± 6.6 | |
| Epithelial | 17.4 ± 1.7 | 16.8 ± 4.7 | |
| Total BAL cells | 68.2 ± 10.6 | 234.3 ± 18.5 | |
| 14 d | Neutrophils | 1.1 ± 0.4 | 29.2 ± 5.4 |
| Macrophages | 53.4 ± 11.6 | 59.1 ± 9.5 | |
| Eosinophils | 0.4 ± 0.3 | 0.9 ± 0.3 | |
| Lymphocytes | 0.2 ± 0.1 | 1.6 ± 0.4 | |
| Epithelial | 27.3 ± 6.7 | 26.3 ± 1.7 | |
| Total BAL cells | 98.8 ± 8.2 | 117.1 ± 15.4 | |
| 42 d | Neutrophils | 0.7 ± 0.3 | 30.5 ± 4.9 |
| Macrophages | 37.5 ± 2.5 | 97.1 ± 10.8 | |
| Eosinophils | 0.5 ± 0.2 | 3.8 ± 1.3 | |
| Lymphocytes | 0.0 ± 0.0 | 0.8 ± 0.7 | |
| Epithelial | 17.4 ± 2.2 | 30.3 ± 4.7 | |
| Total BAL cells | 56.1 ± 4.5 | 162.5 ± 19.7 | |
h — hour; d — day.
p < 0.05.
p < 0.01.
p < 0.001.
Fig. 1DNA strand break determined using the comet assay in BAL cells and lung tissues. DNA strand breaks were quantified as TL and %TDNA in BAL (a) and (b), and in lung tissue (c) and (d) respectively. Statistical significance compared to vehicle controls is indicated by *p < 0.05 and **p < 0.01, respectively.
Fig. 2Genes significantly differentially expressed in response to CBNP exposure. (a) Total number of genes differentially expressed at each post-exposure time-point. (b) Common and unique genes from each post-exposure time-point. Red bars/lines indicate up-regulated and green bars/lines indicate down-regulated genes.
Fold changes of genes that were differentially expressed across either six or five post-exposure time-points in CBNP exposed versus control mice.
| Gene name | Gene symbol | 3 h | 1 d | 2 d | 3 d | 4 d | 5 d | 14 d | 42 d |
|---|---|---|---|---|---|---|---|---|---|
| Common to 6 post-exposure time-points | |||||||||
| CD14 antigen | Cd14 | 1.7 | 1.6 | 2.3 | 1.7 | – | – | 1.8 | 2.4 |
| Chemokine (C–C motif) ligand 12 | Ccl12 | 1.7 | 1.8 | 1.5 | 1.7 | – | – | 1.8 | 1.6 |
| Chemokine (C–C motif) ligand 2 | Ccl2 | 3.3 | 2.0 | 3.0 | 2.1 | – | – | 2.1 | 2.4 |
| Chemokine (C–C motif) ligand 7 | Ccl7 | 3.2 | 2.4 | 3.0 | 2.4 | – | – | 2.4 | 3.0 |
| Chemokine (C–X–C motif) ligand 1 | Cxcl1 | 9.3 | 2.1 | 2.8 | 2.2 | – | – | 3.0 | 2.7 |
| Chemokine (C–X–C motif) ligand 5 | Cxcl5 | 8.2 | 4.2 | 11.7 | 5.2 | – | – | 6.0 | 13.8 |
| Chemokine (C–X–C motif) receptor 1 | Cxcr1 | – | – | 1.9 | 1.6 | 1.8 | 1.5 | 2.3 | 2.7 |
| D site albumin promoter binding protein | Dbp | − 3.6 | 2.9 | − 1.7 | 2.2 | − 1.9 | – | – | − 3.0 |
| Expressed sequence AA467197 | AA467197 | 2.5 | 2.0 | 2.3 | 1.8 | – | – | 3.8 | 4.7 |
| Leukocyte immunoglobulin-like receptor, subfamily B, member 4 | Lilrb4 | 1.6 | 1.8 | 1.7 | 1.5 | – | – | 2.1 | 2.3 |
| Lymphocyte antigen 6 complex, locus F | Ly6f | – | 2.9 | 3.3 | 3.3 | 1.6 | – | 8.0 | 9.0 |
| Serum amyloid A 1 | Saa1 | 3.8 | 6.4 | 3.7 | 2.3 | – | – | 2.2 | 2.4 |
| Serum amyloid A 3 | Saa3 | 7.1 | 30.4 | 12.4 | 8.0 | – | – | 9.7 | 9.1 |
| Common to 5 post-exposure time-points | |||||||||
| Aryl hydrocarbon receptor nuclear translocator-like | Arntl | 1.8 | − 1.6 | – | − 1.6 | 1.6 | – | – | 1.7 |
| Brevican | Bcan | – | − 1.7 | − 1.6 | − 1.5 | – | – | − 1.6 | − 2.1 |
| Cholesterol 25-hydroxylase | Ch25h | 4.0 | 1.6 | – | 1.7 | – | – | 2.9 | 2.7 |
| Colony stimulating factor 2 (granulocyte-macrophage) | Csf2 | 1.6 | 2.2 | – | 1.8 | – | – | 1.7 | 1.6 |
| Chemokine (C–X–C motif) ligand 10 | Cxcl10 | 3.9 | 2.3 | 2.1 | – | – | 1.7 | – | 1.9 |
| Glutathione S-transferase, alpha 2 (Yc2) | Gsta2 | – | − 1.8 | − 1.6 | – | − 1.5 | – | − 1.5 | − 1.6 |
| Interleukin 33 | Il33 | − 1.7 | 1.6 | 2.0 | 1.7 | – | – | – | 1.7 |
| Lipocalin 2 | Lcn2 | – | 3.1 | 2.9 | 2.5 | – | – | 3.3 | 3.5 |
| Lymphocyte antigen 6 complex, locus I | Ly6i | – | 2.8 | 3.2 | 3.2 | – | – | 8.0 | 9.3 |
| NADPH oxidase activator 1 | Noxa1 | – | 1.8 | 1.8 | 1.6 | – | – | 3.3 | 2.0 |
| NADPH oxidase organizer 1 | Noxo1 | – | 2.2 | 2.6 | 2.7 | – | – | 3.8 | 3.9 |
| Orosomucoid 2 | Orm2 | – | 3.7 | 1.7 | 1.6 | – | – | 3.0 | 1.7 |
| Polymeric immunoglobulin receptor | Pigr | – | 1.9 | 2.2 | 2.4 | – | – | 2.4 | 2.8 |
| STEAP family member 4 | Steap4 | 1.7 | 1.7 | – | 1.5 | – | – | 1.9 | 2.1 |
| Tissue inhibitor of metalloproteinase 1 | Timp1 | 2.6 | 3.8 | 3.1 | 2.1 | – | – | 1.7 | – |
| WAP four-disulfide core domain 17 | Wfdc17 | – | 2.4 | – | 1.9 | 1.7 | – | 4.0 | 5.1 |
All genes had a p < 0.05; “–” indicates that gene in that specific time-point did not pass the selection criteria. h — hour; d — day.
Fold changes of genes that were differentially expressed across four post-exposure time-points in CBNP exposed versus control mice.
| Gene name | Gene symbol | 3 h | 1 d | 2 d | 3 d | 4 d | 5 d | 14 d | 42 d |
|---|---|---|---|---|---|---|---|---|---|
| Amiloride binding protein 1 | Abp1 | − 1.7 | – | − 1.9 | 1.8 | − 1.6 | – | – | – |
| Angiopoietin-like 4 | Angptl4 | 5.2 | − 2.1 | 1.7 | – | 2.2 | – | – | – |
| Asialoglycoprotein receptor 1 | Asgr1 | – | − 2.2 | − 1.8 | – | − 1.8 | – | − 2.2 | – |
| Cathepsin K | Ctsk | – | – | 1.9 | 2.0 | – | – | 2.6 | 2.5 |
| Cell adhesion molecule with homology to L1CAM | Chl1 | – | 1.5 | 1.6 | 1.6 | – | – | – | 1.5 |
| Ceruloplasmin | Cp | 1.5 | – | 1.9 | 1.7 | – | – | – | 1.5 |
| Chemokine (C-C motif) receptor-like 1 | Ccrl1 | − 2.0 | − 1.9 | − 1.6 | − 1.8 | – | – | – | – |
| Complement component 3 | C3 | – | 1.5 | 1.6 | – | – | – | 1.8 | 1.8 |
| C-type lectin domain family 4, member d | Clec4d | – | 1.9 | 1.9 | – | – | – | 2.1 | 2.4 |
| Cytidine 5′-triphosphate synthase | Ctps | 1.9 | 1.9 | 1.6 | – | – | – | 1.5 | – |
| Cytochrome P450, family 2, subfamily a, polypeptide 4 | Cyp2a4 | – | – | − 1.9 | – | − 2.3 | − 2.3 | − 2.2 | – |
| Eosinophil-associated, ribonuclease A family, member 6 | Ear6 | – | – | 1.6 | 1.7 | – | – | 2.3 | 1.7 |
| Glycoprotein (transmembrane) nmb | Gpnmb | – | – | 2.0 | 2.0 | – | – | 2.3 | 3.4 |
| Growth differentiation factor 15 | Gdf15 | 1.7 | – | 1.6 | – | – | – | 1.7 | 1.9 |
| Hemopexin | Hpx | 2.7 | 2.6 | 1.9 | – | – | – | 1.6 | – |
| Immunoresponsive gene 1 | Irg1 | – | 1.9 | 3.2 | – | – | – | 1.8 | 2.7 |
| Inter alpha-trypsin inhibitor, heavy chain 4 | Itih4 | – | 1.5 | – | 1.7 | – | – | 1.9 | 2.4 |
| Interleukin 1 receptor, type II | Il1r2 | 2.7 | 2.0 | 1.5 | – | – | – | 1.6 | – |
| Interleukin 4 induced 1 | Il4i1 | – | 1.6 | 1.7 | – | – | – | 2.0 | 2.2 |
| LincRNA:chr1:134867906-134885481_R | – | 1.8 | – | – | – | – | 1.6 | 1.8 | 2.6 |
| LincRNA:chr10:93774693-93893616_F | – | − 1.5 | – | − 1.7 | − 1.5 | – | 1.6 | – | – |
| LincRNA:chr12:5303823-5379098_R | – | 1.9 | − 1.7 | – | – | – | 1.7 | 1.9 | – |
| LincRNA:chr18:35967933-35986564_F | – | 1.7 | – | – | – | – | 1.8 | 1.9 | 1.8 |
| LincRNA:chr18:63525907-63526504_R | – | − 1.5 | – | − 1.8 | – | – | − 1.6 | − 1.5 | – |
| LincRNA:chr8:80581177-80621652_F | – | 1.6 | – | – | – | – | 1.5 | 1.6 | 1.5 |
| Mab-21-like 3 ( | Mab21l3 | – | 1.6 | 1.9 | – | – | – | 1.8 | 2.0 |
| Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha | Nfkbia | 2.8 | – | – | – | – | 1.5 | 1.5 | 1.6 |
| Palmdelphin | Palmd | − 1.8 | – | − 1.7 | − 1.6 | – | 1.5 | – | – |
| Predicted gene 3161 | Gm3161 | − 1.6 | – | – | 1.6 | – | − 1.6 | – | − 1.5 |
| Protein Z, vitamin K-dependent plasma glycoprotein | Proz | 1.6 | 1.8 | – | – | – | – | 2.2 | 3.6 |
| Serine peptidase inhibitor, Kazal type 5 | Spink5 | 1.5 | 2.0 | – | 1.5 | – | – | 1.8 | – |
| Solute carrier family 26, member 4 | Slc26a4 | – | – | 2.3 | 3.0 | – | – | 9.3 | 8.2 |
| Tumor necrosis factor receptor superfamily, member 9 | Tnfrsf9 | – | 1.7 | – | 1.7 | – | – | 1.6 | 1.6 |
| Vanin 1 | Vnn1 | – | 1.9 | – | 1.6 | – | – | 2.9 | 2.3 |
| Vanin 3 | Vnn3 | – | 2.2 | – | 1.6 | – | – | 2.3 | 1.7 |
All genes had p < 0.05; “–” indicates that gene in that specific time-point did not pass the selection criteria. h — hour; d — day.
Fig. 3The number of unique genes differentially expressed at each time-point following CBNP exposure.
Fig. 4(a) Common and unique GO biological processes that were significantly enriched at each CBNP post-exposure time-point. (b) Enrichment of immune-inflammatory GO processes follows a biphasic expression pattern; all of these processes were enriched 3 h, and 1, 2, 3, 14, and 42 d post-exposure. No immune-inflammatory GO processes were enriched 4 or 5 d post-exposure.
Genes involved in acute phase response GO processes that were differentially expressed 3 h, 1 d, and 14 d post-exposure to CBNPs.
| Genbank accession | Gene name | Gene symbol | 3 h | 1 d | 14 d | |||
|---|---|---|---|---|---|---|---|---|
| P-value | Fold change | P-value | Fold change | P-value | Fold change | |||
| NM_013465 | Alpha-2-hs-glycoprotein | Ahsg | < 0.001 | 1.8 | – | – | – | – |
| NM_031168 | Interleukin 6 | Il6 | < 0.001 | 4.4 | – | – | – | – |
| NM_008768 | Orosomucoid 1 | Orm1 | – | – | < 0.001 | 2.7 | < 0.001 | 2.1 |
| NM_011016 | Orosomucoid 2 | Orm2 | – | – | < 0.001 | 3.7 | < 0.001 | 3.0 |
| NM_011260 | Regenerating islet-derived 3 gamma | Reg3g | – | – | 0.02 | − 6.7 | – | – |
| NM_009117 | Serum amyloid a 1 | Saa1 | < 0.001 | 3.8 | < 0.001 | 6.4 | < 0.001 | 2.2 |
| NM_011314 | Serum amyloid a 2 | Saa2 | < 0.001 | 6.6 | < 0.001 | 3.9 | – | – |
| NM_011315 | Serum amyloid a 3 | Saa3 | < 0.001 | 7.1 | < 0.001 | 30.4 | < 0.001 | 9.7 |
| NM_009243 | Serine (or cysteine) peptidase inhibitor, clade a, member 1a | Serpina1a | < 0.001 | 2.5 | – | – | – | – |
| NM_009252 | Serine (or cysteine) peptidase inhibitor, clade a, member 3n | Serpina3n | < 0.001 | 2.2 | < 0.001 | 2.2 | 0.01 | 1.6 |
“–” indicates that gene in that specific time-point did not pass the selection criteria. h — hour; d — day.
Fig. 5Biological pathways that were significantly enriched at each CBNP post-exposure time-point.
Fig. 6Biphasic enrichment pattern of immune-inflammatory pathways following CBNP exposure in the lungs of C57BL/6 mice. The majority of these inflammatory pathways were enriched 3 h, 1, 2, 14, and 42 d post-exposure.
Fig. 7Genes identified as significantly differentially expressed using DNA microarrays validated by RT-qPCR.
Genes differentially expressed in response to CBNP exposure that were similarly altered in response to cigarette smoke or viral exposure.
| Genes expressed in response to CBNP exposure | Study reference | |||
|---|---|---|---|---|
| Gene name | Gene symbol | Gene ID | Cigarette smoke exposure | Viral exposure |
| Chemokine (C–C motif) ligand 17 | Ccl17 | NM_011332 | ||
| Chemokine (C–C motif) ligand 2 | Ccl2 | NM_011333 | ||
| Chemokine (C–C motif) ligand 4 | Ccl4 | NM_013652 | — | |
| Chemokine (C–C motif) ligand 5 | Ccl5 | NM_013653 | ||
| Chemokine (C–C motif) ligand 7 | Ccl7 | NM_013654 | ||
| Colony stimulating factor 2 (granulocyte-macrophage) | Csf2 | NM_009969 | ||
| Chemokine (C–X–C motif) ligand 1 | Cxcl1 | NM_008176 | ||
| Chemokine (C–X–C motif) ligand 10 | Cxcl10 | NM_021274 | ||
| Chemokine (C–X–C motif) ligand 3 | Cxcl3 | NM_203320 | – | |
| Chemokine (C–X–C motif) ligand 5 | Cxcl5 | NM_009141 | ||
| Interleukin 1 beta | Il1b | NM_008361 | ||
| Interleukin 6 | Il6 | NM_031168 | ||
| NADPH oxidase organizer 1 | Noxo1 | NM_027988 | – | |
| Orosomucoid 1 | Orm1 | NM_008768 | ||
| Serum amyloid A 1 | Saa1 | NM_009117 | ||
| Serum amyloid A 3 | Saa3 | NM_011315 | ||
| Tissue inhibitor of metalloproteinase 1 | Timp1 | NM_001044384 | ||
| Vanin 1 | Vnn1 | NM_011704 | ||
| Tumor necrosis factor receptor superfamily, member 9 | Tnfrsf9 | NM_011612 | – | |
| Serum amyloid A 2 | Saa2 | NM_011314 | ||
References related to cigarette smoke (Thomson et al., 2013, Tilton et al., 2013) and virus response studies (Josset et al., 2012).
Fig. 8Schematic representation of genes and biological processes/pathways induced by CBNP exposure at various post-exposure time-points, and their possible long-term consequences. Genes represented in red were up-regulated and those in green were down-regulated.